ArticlePakistan journal of medical sciences2025
The application of Electrochemiluminescence Immunoassay (ECLIA) in the detection of HIV infectious markers in blood screening.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to analyze ELISA, ECLIA, and Western blot (WB) confirmatory test results for HIV-reactive blood donors, compare ECLIA with fourth-generation ELISA reagents, assess the feasibility of using ECLIA for HIV screening, and provide statistical evidence supporting its adoption in blood collection and supply institutions. Methodology: The cross-sectional study was conducted in the Laboratory Department of Yantai Central Blood Station, Shandong, China, from January, 2021 to December, 2023. A total of 130 HIV screening-reactive specimens with ELISA signal-to-cut-off (S/CO) ratios between 0.3 and 0.7 were subjected to ECLIA. Specimens with ELISA S/CO≥1.0, HIV RNA reactivity, or ECLIA S/CO>1 were sent to the Centers for Disease Control (CDC) for WB confirmatory testing. The results were comprehensively analyzed and compared. Results: Among the 130 reactive specimens, 17 tested positive by ECLIA, while 113 were negative. Of the 510 HIV screen-negative specimens, five were positive by ECLIA, and 505 were negative. ECLIA demonstrated a sensitivity of 81.25%, specificity of 96.49%, positive predictive value of 76.47%, and negative predictive value of 97.35%. ECLIA showed excellent concordance with WB confirmatory results, evidenced by the highest area under the operating characteristic (ROC) curve (AUC). The sensitivities of reagent one, reagent two, and ECLIA were consistent at different cut-off values; however, ECLIA exhibited the highest specificity. Conclusion: ECLIA exhibits superior agreement with WB confirmatory tests, higher specificity, and positive predictive values compared to ELISA reagents, supporting its widespread use in blood screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.